The Germany Neurology Clinical Trials market is projected to grow from $191.4 Mn in 2022 to $256 Mn by 2030, registering a CAGR of 3.7% during the forecast period of 2022 - 2030. The market will be driven by the rising frequency of neurological illnesses such as Alzheimer's, Parkinson's, multiple sclerosis, and epilepsy and regulatory frameworks that encourage clinical trials. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis, Pfizer & Bayer.
The Germany Neurology Clinical Trials market is projected to grow from $191.4 Mn in 2022 to $256 Mn by 2030, registering a CAGR of 3.7% during the forecast period of 2022 - 2030. Germany spends 12.8 % of its GDP on healthcare in 2021. For years, overall health spending as a proportion of GDP has grown. Germany has an extraordinary reputation for healthcare, combined with considerable governmental funding for the pharmaceutical business and a number of notable institutions that partner with the industry, such as Bayer-Schering Pharma with the University of Cologne. For ages, Germany has been a leader in pharmaceutical R&D.
In recent years, Germany has been a popular destination for clinical trials in neurology, particularly in the areas of neurodegenerative diseases such as Alzheimer's and Parkinson's. The country also has a strong focus on research related to multiple sclerosis, epilepsy, and stroke. In Germany, neurology clinical trials are normally carried out at specialist medical facilities and hospitals with well-established infrastructure and competent professionals.
Market Growth Drivers
The German healthcare system is well-known for its excellent quality and accessibility, which makes it an appealing location for clinical trials. Also, the nation has a robust research and development (R&D) infrastructure, which is crucial for performing clinical trials. The rising frequency of neurological illnesses such as Alzheimer's, Parkinson's, multiple sclerosis, and epilepsy, among others, is one of the market's key drivers. Germany has a rapidly ageing population, which is likely to substantially raise the need for neurology clinical trials in the nation. Another important determinant is the availability of modern healthcare infrastructure, trained medical practitioners, and well-established regulatory frameworks that encourage clinical trials.
Market Restraints
There are various factors that may have an influence on the neurology clinical trials industry in Germany. The rising expense of clinical trials is one of the primary impediments. Conducting clinical trials is an expensive and time-consuming procedure, and many SMEs may struggle to acquire financing for their study. The regulatory cost associated with clinical trials is another constraint. The German regulatory environment is well-known for being stringent and complicated, which may be difficult for enterprises unfamiliar with the system. This might cause delays in securing regulatory permission for clinical studies, affecting the duration and expense of the research.
Key Players
In June 2022, Biogen invested more than $700 million in Alectos' preclinical oral Parkinson's medication to strengthen its pipeline.
July 2021, GlaxoSmithKline plc and Alector announced a strategic collaborative effort to develop and commercialise two clinical-stage, potential first-in-class monoclonal antibodies (AL001 and AL101) designed to elevate progranulin (PGRN) levels, that is linked to multiple neurodegenerative disorders, making it one of the most appealing genetically validated targets for the development of new immuno-neurology treatments.
In Germany, various regulatory authorities, including the Federal Institute for Drugs and Medical Devices (BfArM) and the Ethics Committee, are in charge of reviewing and authorizing clinical studies ensuring they are conducted in compliance with the German Medicines Act and the EU Clinical Trials Regulation. These regulatory authorities guarantee that clinical trials adhere to ethical and safety requirements, as well as that participants' rights and welfare are respected.
The German statutory health insurance system (GKV) is entrusted with covering the expenses of medical treatments, including those resulting from clinical trials, in terms of reimbursement. The GKV reimburses the expenses of therapies that have been shown in clinical studies to be effective and cost-efficient. The Federal Joint Committee (G-BA), an impartial organisation that analyses the benefits and costs of medical treatments, makes the decision to pay for treatment.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Clinical Trials Regulation in Country
1.6 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
6. Methodology and Scope
By Phase (Revenue, USD Billion):
By Study Design Outlook (Revenue, USD Billion):
By Indication Outlook (Revenue, USD Billion):
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses
Need more?